Antibacterial Efficacy of the Compound Preparation of Traditional Chinese Drug on System Fungi Reside in Faecal Specimen of Pigeon

2012 ◽  
Vol 518-523 ◽  
pp. 5514-5517 ◽  
Author(s):  
Lian Lan Ma ◽  
Zhi Chun Liu ◽  
Xiao Yuan Wang ◽  
Xiao Yun Wu
Keyword(s):  
Candida Albicans ◽  
Cryptococcus Neoformans ◽  
Drug Concentration ◽  
Chinese Drug ◽  
Faecal Specimen ◽  
Sterile Saline ◽  
Gram Staining ◽  
Chlamydospore Formation ◽  
Positive Rate ◽  
Acid Test

To investigate the efficacy of the compound preparation of traditional Chinese drug which is named KZY-2) on system fungi reside in faecal specimen of pigeon, the 66 faecal specimen of pigeon were collected from columbary of local park and residents.Each specimen which weigh 2.0g was mixed with 10ml sterile saline and the supernatant which volume was 1ml was incubated with the same volume drug which concentration were 200mɡ/ml,100mɡ/ml and 50mɡ/ml respectively at 37°C.After 24h,48h and 72h, the isolated positive rates of Cryptococcus neoformans and Candida albicans were calculated. Candida albicans was identified by gram staining, budding development, chlamydospore formation, sugar fermented test,sugar assimilated test and Cryptococcus neoformans was identified by gram staining,sugar fermented test,sugar assimilated test,urease tests,caffeic acid test, Hiss capsule staining.Results showed that the isolated positive rates of Cryptococcus neoformans and Candida albicans were 27.3%（18/66） and 16.7%（11/66） without drug action, KZY-2 could reduce the isolated positive rates of Cryptococcus neoformans and Candida albicans(P<0.05 and P<0.05).The drug concentration and action time could significantly affect the isolated positive rate which was negative correlation between them, higher drug concentration and longer incubation time,more lower the positive rate, especially the isolated positive rates of Cryptococcus neoformans are reduced 77.7%（6.1/27.3）which incubated with 200mɡ/ml drug after 72h compared with the control group.These results indicate The KZY-2 have good germicidal efficacy on Cryptococcus neoformans and Candida albicans isolated from faecal specimen of pigeon.

scholarly journals Candida albicans isolated from post-operative penetrating keratoplasty patient: Case report

2014 ◽  
Vol 5 (3) ◽  
pp. 116-119
Author(s):  
Abhishek Chandra ◽  
Munesh Kumar Gupta ◽  
Ragini Tilak
Keyword(s):  
Candida Albicans ◽  
Case Report ◽  
Amphotericin B ◽  
Penetrating Keratoplasty ◽  
Antifungal Susceptibility ◽  
Medical Science ◽  
Eye Drops ◽  
Gram Staining ◽  
Chlamydospore Formation ◽  
Culture Characteristics

We report a case report of Candida albicans suture infiltrate on 3rd post-op day in a 53 year female operated for penetrating keratoplasty. Candida albicans was identified by KOH mount, Gram Staining, germ tube, growth at 450C, chlamydospore formation and light green color on CHROMagar with sugar assimilation and culture characteristics. Despite being susceptible to Fluconazole by broth microdilution, patient did not respond to 0.3% fluconazole eye drops. On antifungal susceptibility testing by CLSI44A, it was susceptible to only Amphotericin B (100units). Patient was then started on 0.15% fortified amphotericin B eye drops resulting in complete resolution of infiltrates. Asian Journal of Medical Science, Volume-5(3) 2014: 116-119 http://dx.doi.org/10.3126/ajms.v5i3.8669 

scholarly journals New culture medium for the presumptive identificaion of Candida albicans and Cryptococcus neoformans

1977 ◽  
Vol 5 (2) ◽  
pp. 236-243
Author(s):  
W H Fleming ◽  
J M Hopkins ◽  
G A Land
Keyword(s):  
Candida Albicans ◽  
Cryptococcus Neoformans ◽  
Morphological Changes ◽  
Tween 80 ◽  
Brown Pigment ◽  
Chlamydospore Formation ◽  
Time Required ◽  
Germ Tubes ◽  
Light Brown Color ◽  
Brown Color

A new medium composed of Tween 80, oxgall, caffeic acid, and Davis agar (TOC) that provides for the rapid presumptive identification of Candida albicans and Cryptococcus neoformans is described herein. C. albicans is differentiated from other yeasts by the sequential production of germ tubes and chlamydospores. In a comparison with cormeal agar control plates, there was an increase of chlamydospore-forming strains of C. albicans (97.1% versus 87.2%) and a decrease in the time required for chlamydospore formation (24 h versus 48 h). C. neoformans produced a brown pigment of TOC, which is specific for its identification, thus differentiating it from the other yeasts. A comparison of 24-h pigment production by C. neoformans on TOC with that of birdseed agar showed a dark, coffee brown color in the former cultures and a light brown color in the latter. The change in pigmentation of C. neoformans, as well as morphological changes in C. albicans, can be induced within 3 to 12 h and in not more than 24 h on the TOC medium.

scholarly journals Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy

mSphere ◽  
2019 ◽  
Vol 4 (5) ◽  
Author(s):  
Suresh Ambati ◽  
Emma C. Ellis ◽  
Jianfeng Lin ◽  
Xiaorong Lin ◽  
Zachary A. Lewis ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Aspergillus Fumigatus ◽  
Effective Dose ◽  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Antifungal Drugs ◽  
Extracellular Matrices ◽  
Content Type ◽  
Order Of Magnitude ◽  
Life Threatening

ABSTRACT Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus cause life-threatening candidiasis, cryptococcosis, and aspergillosis, resulting in several hundred thousand deaths annually. The patients at the greatest risk of developing these life-threatening invasive fungal infections have weakened immune systems. The vulnerable population is increasing due to rising numbers of immunocompromised individuals as a result of HIV infection or immunosuppressed individuals receiving anticancer therapies and/or stem cell or organ transplants. While patients are treated with antifungals such as amphotericin B, all antifungals have serious limitations due to lack of sufficient fungicidal effect and/or host toxicity. Even with treatment, 1-year survival rates are low. We explored methods of increasing drug effectiveness by designing fungicide-loaded liposomes specifically targeted to fungal cells. Most pathogenic fungi are encased in cell walls and exopolysaccharide matrices rich in mannans. Dectin-2 is a mammalian innate immune membrane receptor that binds as a dimer to mannans and signals fungal infection. We coated amphotericin-loaded liposomes with monomers of Dectin-2’s mannan-binding domain, sDectin-2. sDectin monomers were free to float in the lipid membrane and form dimers that bind mannan substrates. sDectin-2-coated liposomes bound orders of magnitude more efficiently to the extracellular matrices of several developmental stages of C. albicans, C. neoformans, and A. fumigatus than untargeted control liposomes. Dectin-2-coated amphotericin B-loaded liposomes reduced the growth and viability of all three species more than an order of magnitude more efficiently than untargeted control liposomes and dramatically decreased the effective dose. Future efforts focus on examining pan-antifungal targeted liposomal drugs in animal models of fungal diseases. IMPORTANCE Invasive fungal diseases caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus have mortality rates ranging from 10 to 95%. Individual patient costs may exceed $100,000 in the United States. All antifungals in current use have serious limitations due to host toxicity and/or insufficient fungal cell killing that results in recurrent infections. Few new antifungal drugs have been introduced in the last 2 decades. Hence, there is a critical need for improved antifungal therapeutics. By targeting antifungal-loaded liposomes to α-mannans in the extracellular matrices secreted by these fungi, we dramatically reduced the effective dose of drug. Dectin-2-coated liposomes loaded with amphotericin B bound 50- to 150-fold more strongly to C. albicans, C. neoformans, and A. fumigatus than untargeted liposomes and killed these fungi more than an order of magnitude more efficiently. Targeting drug-loaded liposomes specifically to fungal cells has the potential to greatly enhance the efficacy of most antifungal drugs.

scholarly journals The Cek1 and Hog1 Mitogen-Activated Protein Kinases Play Complementary Roles in Cell Wall Biogenesis and Chlamydospore Formation in the Fungal Pathogen Candida albicans

2006 ◽  
Vol 5 (2) ◽  
pp. 347-358 ◽  
Author(s):  
B. Eisman ◽  
R. Alonso-Monge ◽  
E. Román ◽  
D. Arana ◽  
C. Nombela ◽  
...  
Keyword(s):  
Cell Wall ◽  
Candida Albicans ◽  
Map Kinase ◽  
Fungal Pathogen ◽  
Hog Pathway ◽  
Cell Wall Biogenesis ◽  
Chlamydospore Formation ◽  
Mitogen Activated Protein ◽  
Morphological Transitions ◽  
Relationship Of

ABSTRACT The Hog1 mitogen-activated protein (MAP) kinase mediates an adaptive response to both osmotic and oxidative stress in the fungal pathogen Candida albicans. This protein also participates in two distinct morphogenetic processes, namely the yeast-to-hypha transition (as a repressor) and chlamydospore formation (as an inducer). We show here that repression of filamentous growth occurs both under serum limitation and under other partially inducing conditions, such as low temperature, low pH, or nitrogen starvation. To understand the relationship of the HOG pathway to other MAP kinase cascades that also play a role in morphological transitions, we have constructed and characterized a set of double mutants in which we deleted both the HOG1 gene and other signaling elements (the CST20, CLA4, and HST7 kinases, the CPH1 and EFG1 transcription factors, and the CPP1 protein phosphatase). We also show that Hog1 prevents the yeast-to-hypha switch independent of all the elements analyzed and that the inability of the hog1 mutants to form chlamydospores is suppressed when additional elements of the CEK1 pathway (CST20 or HST7) are altered. Finally, we report that Hog1 represses the activation of the Cek1 MAP kinase under basal conditions and that Cek1 activation correlates with resistance to certain cell wall inhibitors (such as Congo red), demonstrating a role for this pathway in cell wall biogenesis.

scholarly journals Effect of the metalic salts on the pseudohyphae and chlamydospore formation of Candida albicans

1973 ◽  
Vol 14 (2) ◽  
pp. 106-108_1
Author(s):  
Tomi TAMAMURA ◽  
Teruo ISODA ◽  
Fukumitsu YAMAGUCHI ◽  
Yoshio SCHÖBL
Keyword(s):  
Candida Albicans ◽  
Chlamydospore Formation

scholarly journals СИНТЕЗ ТА ДОСЛІДЖЕННЯ АНТИМІКРОБНОЇ АКТИВНОСТІ ДЕЯКИХ ПІРАЗОЛЗАМІЩЕНИХ 7H-[1,2,4]ТРИАЗОЛО[3,4-B][1,3,4]ТІАДІАЗИНІВ

2021 ◽  
pp. 5-13
Author(s):  
I. I. Myrko ◽  
T. I. Chaban ◽  
V. V. Ogurtsov ◽  
V. S. Matiychuk
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Candida Albicans ◽  
Drug Discovery ◽  
Klebsiella Pneumoniae ◽  
Acinetobacter Baumannii ◽  
Cryptococcus Neoformans ◽  
Antimicrobial Drug

Мета роботи. Здійснити синтез деяких нових піразолзаміщених 7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазинів та провести дослідження антимікробних властивостей синтезованих сполук. Матеріали і методи. Органічний синтез, ЯМР-спектроскопія, елементний аналіз, фармакологічний скринінг. Результати й обговорення. У результаті взаємодії eтил (2Z)-хлоро(фенілгідразоно)ацетатів з ацетилацетоном було отримано етил 4-ацетил-5-метил-1-феніл-1H-піразол-3-карбоксилати. Зазначені сполуки піддали бромуванню, що дозволило одержати цільові бромкетони. Синтезовані на даній стадії етил 1-арил-4-(бромацетил)-5-метил-1Н-піразол-3-карбоксилати було введено у взаємодію з 4-аміно-5-арил(гетарил)-2,4-дигідро-3Н-1,2,4-триазол-3-тіонами з подальшим формуванням 1,3,4-тіадіазольного циклу та отриманням відповідних етил 1-арил-4-{3-арил(гетарил)-7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазин-6-іл)}-5-метил-1H-піразол-3-карбоксилатів. Структура синтезованих сполук підтверджена даними елементного аналізу та ЯМР спектроскопією. В рамках міжнародного проекту "The Community for Antimicrobial Drug Discovery" (CO-ADD) за підтримки Wellcome Trust (Великобританія) і університету Квінсленда (Австралія) для синтезованих сполук здійснено скринінг антимікробної активності. Як тестові мікроорганізми використовували п'ять штамів бактерій: Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603, Acinetobacter baumannii ATCC 19606, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 43300 та двох штамів грибків: Candida albicans ATCC 90028 і Cryptococcus neoformans ATCC 208821. Встановлено, що досліджувані сполуки виявляють різноманітну дію, від практично повної її відсутності до виразного антимікробного ефекту. Висновки. Здійснено синтез 12 нових етил 1-арил-4-{3-арил(гетарил)-7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазин-6-іл)}-5-метил-1H-піразол-3-карбоксилатів. Зазначені речовини отримані шляхом взаємодії відповідних етил 1-арил-4-(бромацетил)-5-метил-1Н-піразол-3-карбоксилатів з 4-аміно-5-арил(гетарил)-2,4-дигідро-3Н-1,2,4-триазол-3-тіонами. Дослідження антимікробної активності синтезованих сполук демонструють потенціал пошуку антимікробних агентів серед зазначеного класу сполук.

scholarly journals Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box

mSphere ◽  
2018 ◽  
Vol 3 (2) ◽  
Author(s):  
Eric H. Jung ◽  
David J. Meyers ◽  
Jürgen Bosch ◽  
Arturo Casadevall
Keyword(s):  
Candida Albicans ◽  
Antifungal Activity ◽  
Cryptococcus Neoformans ◽  
Fungal Pathogens ◽  
Pathogenic Fungi ◽  
Cryptococcus Gattii ◽  
Antifungal Drugs ◽  
Resistant Bacteria ◽  
Animal Cells ◽  
Malaria Box

ABSTRACTSimilarities in fungal and animal cells make antifungal discovery efforts more difficult than those for other classes of antimicrobial drugs. Currently, there are only three major classes of antifungal drugs used for the treatment of systemic fungal diseases: polyenes, azoles, and echinocandins. Even in situations where the offending fungal organism is susceptible to the available drugs, treatment courses can be lengthy and unsatisfactory, since eradication of infection is often very difficult, especially in individuals with impaired immunity. Consequently, there is a need for new and more effective antifungal drugs. We have identified compounds with significant antifungal activity in the Malaria Box (Medicines for Malaria Ventures, Geneva, Switzerland) that have higher efficacy than some of the currently used antifungal drugs. Our best candidate, MMV665943 (IUPAC name 4-[6-[[2-(4-aminophenyl)-3H-benzimidazol-5-yl]methyl]-1H-benzimidazol-2-yl]aniline), here referred to as DM262, showed 16- to 32-fold-higher activity than fluconazole againstCryptococcus neoformans. There was also significant antifungal activity in other fungal species with known antifungal resistance, such asLomentospora prolificansandCryptococcus gattii. Antifungal activity was also observed against a common fungus,Candida albicans. These results are important because they offer a potentially new class of antifungal drugs and the repurposing of currently available therapeutics.IMPORTANCEMuch like the recent increase in drug-resistant bacteria, there is a rise in antifungal-resistant strains of pathogenic fungi. There is a need for novel and more potent antifungal therapeutics. Consequently, we investigated a mixed library of drug-like and probe-like compounds with activity inPlasmodiumspp. for activity against two common fungal pathogens,Cryptococcus neoformansandCandida albicans, along with two less common pathogenic species,Lomentospora prolificansandCryptococcus gattii. We uncover a previously uncharacterized drug with higher broad-spectrum antifungal activity than some current treatments. Our findings may eventually lead to a compound added to the arsenal of antifungal therapeutics.

Sign in / Sign up

Export Citation Format

Share Document